- Home
- XXI vs ATAI Comparison
XXI vs ATAI Comparison
Compare XXI & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XXI | ATAI |
|---|---|---|
| Founded | 2025 | 2018 |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | XXI | ATAI |
|---|---|---|
| Price | $5.44 | $5.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $15.88 |
| AVG Volume (30 Days) | 1.4M | ★ 8.7M |
| Earning Date | 06-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,089,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $4.81 | $2.58 |
| 52 Week High | $11.49 | $6.73 |
Technical Indicators
Market Signals| Indicator | XXI | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 39.57 | 65.91 |
| Support Level | N/A | $4.96 |
| Resistance Level | $6.46 | $5.51 |
| Average True Range (ATR) | 0.34 | 0.38 |
| MACD | 0.03 | 0.13 |
| Stochastic Oscillator | 39.19 | 85.65 |
Price Performance
Historical ComparisonAbout XXI Twenty One Capital Inc. Class A Common Stock
Twenty One Capital Inc is engaged in the Bitcoin-related business lines. It engages in two principal activities: actively accumulating Bitcoin and managing its Bitcoin holdings, and commencing development of educational materials and branded content intended to drive increased institutional and retail investor Bitcoin literacy.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.